Status:
COMPLETED
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
Lead Sponsor:
Cytos Biotechnology AG
Conditions:
Perennial Allergic Rhinoconjunctivitis
Allergic Asthma
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house d...
Eligibility Criteria
Inclusion
- Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites
- Mild asthma
- Females only if non-reproductive or agree to practice an effective and accepted method of contraception
Exclusion
- Relevant cardiovascular, renal, pulmonary or endocrine disease
- History of autoimmune disease
- Severe allergies
- History of active infectious disease
- Current diagnosis or history of malignancy
- Relevant neurological or psychiatric disorder
- Pregnancy or lactation
- History of alcohol abuse or other recreational drugs
- Use of an investigational drug within three month before enrolment
- Blood donation within 30 days before enrolment
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00652223
Start Date
March 1 2005
End Date
November 1 2005
Last Update
April 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich, Department of Dermatology
Zurich, Canton of Zurich, Switzerland, 8091